Company intelligence / Profile preview

Lavela

Thane, Maharashtra, Indiaintegrativepro.com ↗

Ownership: Private
Development stage: Commercial

Overview

Clinical studies show that the company's main product, Lavela WS 1265 (Silexan), provides statistically significant relief for occasional anxiety compared to placebo and some conventional agents. It improves relaxation, sleep quality, and reduces nervousness without sedative or habit-forming effects. Results are typically seen after several weeks of use.

Therapeutic areas: Psychiatry
Modalities: Botanical extract (lavender essential oil/Silexan)
Industry: Food & Nutrition

Drug pipeline

1 asset

Lavela WS 1265

Commercial

Indications: Anxiety, Sleep disorders, Stress

Beyond the preview

Go deeper on Lavela.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lavela.

Explore the full profile